United States: These 43 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025
DrugPatentWatch® Estimated Loss of Exclusivity Dates in the United States
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
African Regional IP Organization (ARIPO)
Argentina
Australia
Austria
Brazil
Canada
China
Colombia
Costa Rica
Croatia
Cuba
Cyprus
Denmark
Dominican Republic
Ecuador
El Salvador
Eurasian Patent Organization
European Patent Office
Finland
France
Georgia, Republic of
Germany
Guatemala
Honduras
Hong Kong
Hungary
Israel
Italy
Japan
Jordan
Lithuania
Luxembourg
Malaysia
Mexico
Moldova, Republic of
Montenegro
Morocco
Netherlands
New Zealand
Nicaragua
Norway
Panama
Peru
Philippines
Poland
Portugal
Russian Federation
Saudi Arabia
Serbia
Singapore
Slovenia
South Africa
South Korea
Spain
Taiwan
Tunisia
Turkey
Ukraine
United Kingdom
Uruguay
Viet Nam
World Intellectual Property Organization (WIPO)
Preferred citation:
Friedman, Yali, "United States: These 43 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025" DrugPatentWatch.com thinkBiotech, 2024 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
Friedman, Yali, "United States: These 43 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025" DrugPatentWatch.com thinkBiotech, 2024 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.